Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Evaluation of anticancer properties and molecular mechanisms of action of new hybrid molecules containing uracil skeleton with an exo-cyclic methylene group

2017/25/N/NZ3/01039

Keywords:

apoptosis proliferation anticancer drug multidrug resistance activity of NF-kB ABC transporters

Descriptors:

  • NZ1_1: Molecular biology
  • NZ3_1: Cell biology
  • NZ7_14: Pharmacy, pharmacotherapy, pharmacology

Panel:

NZ3 - Cellular and developmental biology: cell biology, developmental biology, ageing biology, neurobiology

Host institution :

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

woj. łódzkie

Other projects carried out by the institution 

Principal investigator (from the host institution):

dr Angelika Długosz-Pokorska 

Number of co-investigators in the project: 2

Call: PRELUDIUM 13 - announced on 2017-03-15

Amount awarded: 149 700 PLN

Project start date (Y-m-d): 2018-03-22

Project end date (Y-m-d): 2024-09-21

Project duration:: 36 months (the same as in the proposal)

Project status: Project completed

Project description

Download the project description in a pdf file

Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

  • Publication in academic press/journals (4)
  • Articles in post-conference publications (1)
  1. New uracil analog U-332 is an inhibitor of NF-κB in 5-fluorouracil-resistant human leukemia HL-60 cell line
    Authors:
    Angelika Długosz-Pokorska, Marlena Pięta, Jacek Kędzia, Tomasz Janecki, Anna Janecka
    Academic press:
    BMC Pharmacology and Toxicology (rok: 2020, tom: 21, strony: 45301), Wydawca: Springer
    Status:
    Published
    DOI:
    10.1186/s40360-020-0397-4 - link to the publication
  2. New Uracil Analog with Exocyclic Methylidene Group Can Reverse Resistance to Taxol in MCF-7 Cancer Cells.
    Authors:
    Angelika Długosz-Pokorska , Renata Perlikowska , Tomasz Janecki , Anna Janecka
    Academic press:
    Biologics: Targets and Therapy (rok: 2023, tom: 17, strony: 69–83), Wydawca: Dovepress
    Status:
    Published
    DOI:
    10.2147/BTT.S405080 - link to the publication
  3. New uracil analog with exocyclic methylidene group as potential anticancer agent.
    Authors:
    Angelika Długosz-Pokorska, Joanna Drogosz, Marlena Pięta, Tomasz Janecki, Urszula Krajewska, Marek Mirowski, Anna Janecka
    Academic press:
    Anti-Cancer Agents in Medicinal Chemistry (rok: 2020, tom: 20, strony: 359-368), Wydawca: Bentham Science Publishers
    Status:
    Published
    DOI:
    10.2174/1871520619666191211104128 - link to the publication
  4. New uracil analogs as downregulators of ABC transporters in 5-fluorouracil-resistant human leukemia HL-60 cell line.
    Authors:
    Długosz-Pokorska Angelika, Pięta Marlena, Janecki Tomasz, Janecka Anna
    Academic press:
    Molecular Biology Reports (rok: 2019, tom: 46(6), strony: 5831-5839), Wydawca: Springer Science+Business Media
    Status:
    Published
    DOI:
    10.1007/s11033-019-05017-w - link to the publication
  1. New Uracil Analog- U-359 can reverse resistance to Taxol in MCF-7 cancer cells
    Authors:
    Angelika Długosz-Pokorska, Renata Perlikowska, Tomasz Janecki, Anna Janecka
    Conference:
    the 5th BIO Congress (rok: 2023, ), Wydawca: Acta Biochmica Polonica
    Data:
    konferencja 13-16.09.2023
    Status:
    Published

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy